May 29, 2024

Anti Neprilysin Market Dynamics: Advancing Heart Failure Therapies


Anti-Neprilysin or neprilysin inhibitors are a class of medications that work by blocking the enzyme neprilysin, which breaks down natriuretic peptides. These peptides play an important role in regulating blood pressure and sodium balance. By blocking their breakdown, anti-neprilysin drugs increase levels of natriuretic peptides in the body, helping to relax blood vessels and lower blood pressure. The major applications of anti-neprilysin inhibitors include treatment of acute decompensated heart failure and hypertension. They are available in the form of oral tablets and injections and offer several advantages over existing heart failure drugs such as better efficacy and reduced side effects.

The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the anti-neprilysin market is the increasing adoption of combination drugs that contain neprilysin inhibitors along with other heart failure medications. Sacubitril-valsartan, sold under the brand name Entresto, was the first approved neprilysin inhibitor based combination drug for treating heart failure. It combines neprilysin inhibition with angiotensin receptor blocker in a single pill. Studies have shown sacubitril-valsartan provides significantly better efficacy and safety outcomes compared to ACE inhibitors alone in patients. Owing to its advantages, sacubitril-valsartan has gained rapid adoption globally and is driving growth of the overall anti-neprilysin therapeutics market. Other players are also developing novel combination therapies by adding neprilysin inhibitors to existing heart failure drugs thus emerging as a major trend.

Porter’s Analysis

Threat of new entrants: Low due to the high R&D costs involved and established distribution channels of existing players.

Bargaining power of buyers: Moderate due to the availability of alternatives.

Bargaining power of suppliers: Moderate as there are sufficient raw material suppliers.

Threat of new substitutes: High as other hypertension drugs may emerge as new substitutes.

Competitive rivalry: High due to the presence of few established brands.

Key Takeaways

The global Anti-Neprilysin market is expected to witness high growth. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.

North America currently dominates the market and is expected to maintain its lead over the forecast period owing to increasing prevalence of cardiovascular diseases and growing healthcare expenditure in the US and Canada. Asia Pacific is expected to be the fastest growing region in the Anti-Neprilysin market driven by improving healthcare infrastructure, rising geriatric population, and increasing healthcare expenditure in major economies like India and China. With growing urbanization and expanding penetration of medical insurance, the demand for advanced heart failure treatments is rising rapidly in Asia Pacific.

Key players operating in the Anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. BIOPROJET dominates the market with their patented molecule BIP-3029 which is currently under Phase II clinical trials.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it